ketanserin has been researched along with Acute Confusional Senile Dementia in 14 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The binding of the selective 5-HT2 antagonist [3H]ketanserin has been investigated in the temporal cortex of patients with Alzheimer's disease (SDAT), Parkinson's disease (PD), senile dementia of Lewy body type (SDLT) and neuropathologically normal subjects (control)." | 3.68 | Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. ( Cheng, AV; Edwardson, JA; Ferrier, IN; Jabeen, S; McKeith, IG; Morris, CM; Perry, EK; Perry, RH; Sahgal, A, 1991) |
| "In patients with Alzheimer's disease (AD), postmortem and imaging studies have revealed early and prominent reductions in cerebral serotonin 2A (5-HT(2A)) receptors." | 1.38 | Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study. ( Baaré, WF; Frokjaer, VG; Hasselbalch, SG; Kalbitzer, J; Knudsen, GM; Lehel, S; Madsen, K; Marner, L, 2012) |
| " Chronic administration of mCPP (1-(m-chlorophenyl)piperazine) (2 mg/kg bid, i." | 1.31 | Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. ( Arjona, AA; Lee, RK; Pooler, AM; Wurtman, RJ, 2002) |
| "However, the patients with Alzheimer's disease had significantly lower binding than the normal subjects in several brain regions, including the anterior cingulate, prefrontal cortex, and sensorimotor cortex." | 1.30 | PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. ( Ben-Eliezer, D; Cantwell, MN; DeKosky, ST; Greer, PJ; Houck, PR; Lopresti, B; Mathis, CA; Meltzer, CC; Mulsant, BH; Price, JC; Reynolds, CF, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santhosh, L | 1 |
| Estok, KM | 1 |
| Vogel, RS | 1 |
| Tamagnan, GD | 1 |
| Baldwin, RM | 1 |
| Mitsis, EM | 1 |
| Macavoy, MG | 1 |
| Staley, JK | 1 |
| van Dyck, CH | 1 |
| Marner, L | 1 |
| Frokjaer, VG | 1 |
| Kalbitzer, J | 1 |
| Lehel, S | 1 |
| Madsen, K | 1 |
| Baaré, WF | 1 |
| Knudsen, GM | 1 |
| Hasselbalch, SG | 1 |
| Lai, MK | 1 |
| Tsang, SW | 1 |
| Esiri, MM | 1 |
| Francis, PT | 2 |
| Wong, PT | 1 |
| Chen, CP | 2 |
| Arjona, AA | 1 |
| Pooler, AM | 1 |
| Lee, RK | 1 |
| Wurtman, RJ | 1 |
| Holmes, C | 1 |
| McCulley, M | 1 |
| Nicoll, JA | 1 |
| Alder, JT | 1 |
| Crow, TJ | 3 |
| Cross, AJ | 3 |
| Cooper, SJ | 1 |
| Deakin, JF | 1 |
| Ferrier, IN | 3 |
| Johnson, JA | 2 |
| Joseph, MH | 1 |
| Owen, F | 1 |
| Poulter, M | 1 |
| Lofthouse, R | 1 |
| Bloom, SR | 1 |
| Corsellis, JA | 1 |
| Reynolds, GP | 1 |
| Arnold, L | 1 |
| Rossor, MN | 1 |
| Iversen, LL | 1 |
| Mountjoy, CQ | 1 |
| Roth, M | 1 |
| Meltzer, CC | 1 |
| Price, JC | 1 |
| Mathis, CA | 1 |
| Greer, PJ | 1 |
| Cantwell, MN | 1 |
| Houck, PR | 1 |
| Mulsant, BH | 1 |
| Ben-Eliezer, D | 1 |
| Lopresti, B | 1 |
| DeKosky, ST | 1 |
| Reynolds, CF | 1 |
| Andorn, AC | 1 |
| Pappolla, MA | 1 |
| Cheng, AV | 1 |
| Morris, CM | 1 |
| Jabeen, S | 1 |
| Sahgal, A | 1 |
| McKeith, IG | 1 |
| Edwardson, JA | 1 |
| Perry, RH | 1 |
| Perry, EK | 1 |
| DeNoble, VJ | 1 |
| DeNoble, KF | 1 |
| Spencer, KR | 1 |
| Dewar, D | 1 |
| Graham, DI | 1 |
| McCulloch, J | 1 |
| Peters, TJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Kinetic Studies in Whole Body and Brain of [11C]DASB PET Imaging of Serotonin Transporters[NCT00059046] | 20 participants | Observational | 2003-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 other studies available for ketanserin and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Regional distribution and behavioral correlates of 5-HT(2A) receptors in Alzheimer's disease with [(18)F]deuteroaltanserin and PET.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Brain; Brain Mapping; Brief Psychi | 2009 |
Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Carbon Radioisotopes; Cerebral Cortex; Fem | 2012 |
Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aged; Aged, 80 and over; Alzheimer Disease; Autopsy; Binding | 2011 |
Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Body Weight; Brai | 2002 |
Genetic variation in the 5-HT2A receptor and altered neocortical [3H] ketanserin binding in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Female; Genetic Variation; Genotype; Hallucinations; Humans; In Vitro Techn | 2007 |
Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides.
Topics: Aged; Aging; Alzheimer Disease; Binding, Competitive; Biogenic Amines; Brain; Choline O-Acetyltransf | 1984 |
Serotonin receptor changes in dementia of the Alzheimer type.
Topics: Aged; Alzheimer Disease; Choline O-Acetyltransferase; Female; Humans; Hydroxyindoleacetic Acid; Keta | 1984 |
Reduced binding of [3H]ketanserin to cortical 5-ht2 receptors in senile dementia of the Alzheimer type.
Topics: Age Factors; Aged; Alzheimer Disease; Cerebral Cortex; Humans; Ketanserin; Piperidines; Receptors, S | 1984 |
PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders.
Topics: Age Factors; Aged; Alzheimer Disease; Brain; Cerebral Cortex; Depressive Disorder; Female; Fluorine | 1999 |
Catecholamines inhibit lipid peroxidation in young, aged, and Alzheimer's disease brain.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adult; Aged; Aging; Alzheimer Disease; Autopsy; Brain; Catec | 2001 |
Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Hallucinations; Humans; Ketanserin; Lewy Bodie | 1991 |
Protection against hypoxia-induced passive avoidance deficits: interactions between DuP 996 and ketanserin.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Drug Interactions; Hypoxia; Indoles; Ketanserin; Mal | 1991 |
5 HT2 receptors in dementia of Alzheimer type: a quantitative autoradiographic study of frontal cortex and hippocampus.
Topics: Alzheimer Disease; Autoradiography; Choline O-Acetyltransferase; Female; Frontal Lobe; Functional La | 1990 |
Cortical neurochemistry in Alzheimer-type dementia.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Cholinergic Fibers; Endoplasmic Reticulum; Female; Golgi A | 1986 |